The short answer
The FDA has requested that manufacturers remove all language about suicidal ideation and behaviour from the labelling of Saxenda, Wegovy and Zepbound. It follows a meta-analysis of 91 placebo-controlled clinical trials covering 107,910 participants, which found no increased risk of those outcomes.
Key facts
- Date
- 13 January 2026
- Action
- Request to remove warning language from labelling
- Products named
- Saxenda (liraglutide), Wegovy (semaglutide), Zepbound (tirzepatide)
- Trials in the analysis
- 91, placebo-controlled
- Total participants
- 107,910
- GLP-1-treated
- 60,338
- Placebo
- 47,572
- Outcomes assessed
- Suicidal behaviour and ideation, anxiety, depression, irritability, psychosis
- Investigation opened
- July 2023
What was announced
The FDA issued a Drug Safety Communication on 13 January 2026 requesting that application holders remove information regarding the risk of suicidal ideation and behaviour from the labelling of GLP-1 receptor agonist medications. The named products are Saxenda (liraglutide), Wegovy (semaglutide) and Zepbound (tirzepatide). The basis given is a meta-analysis of 91 placebo-controlled clinical trials drawn from across GLP-1 receptor agonist development programmes, comprising 107,910 participants of whom 60,338 received a GLP-1 receptor agonist and 47,572 received placebo. The analysis found no increased risk of suicidal ideation or behaviour, nor of related psychiatric adverse events including anxiety, depression, irritability and psychosis.
How the question arose
The FDA opened a formal investigation in July 2023 following postmarketing reports of suicidal ideation and behaviour in patients using these medications. Postmarketing reports are the earliest and least reliable form of safety information (voluntary, unverified, without a denominator of exposed people), and their function is to prompt investigation rather than to establish anything. That is what happened here. A preliminary Drug Safety Communication in January 2024 reported no clear evidence of causation while noting that the small number of cases in individual trials left the risk estimate uncertain.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
What Europe did, and when
The European Medicines Agency's Pharmacovigilance Risk Assessment Committee reached its conclusion on 12 April 2024, considerably earlier. Having reviewed non-clinical studies, clinical trials, post-marketing surveillance data and additional studies including one based on electronic health records that the agency conducted itself, the PRAC concluded that the available evidence does not support a causal association between the GLP-1 receptor agonists dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide and suicidal and self-injurious thoughts and actions. Its stated consequence was that no update to the product information was warranted. The UK's MHRA reached a similar conclusion. Strictly, the European decision was not to change the labelling, which is a different act from the FDA's later decision to remove text from it.
Why the trial-level evidence was decisive
The recurring problem in this question is confounding. People prescribed weight-management medicines have, as a group, higher baseline rates of depression and related conditions than the general population, partly because obesity and depression co-occur, partly because the decision to seek treatment is itself associated with distress. Any observational comparison inherits that. A published meta-analysis of observational studies illustrates the consequence: pooling four studies gave a risk ratio of 0.568 with a 95% confidence interval from 0.077 to 4.205 and heterogeneity of 98%, an estimate compatible with almost any conclusion. Randomised allocation across 91 trials removes the confounding by construction and supplies the event numbers that individual trials lacked.
What this does not establish
That the risk is zero. A large randomised analysis constrains how large an effect could have escaped detection; it does not prove absence, and no study design does. It also does not extend beyond the populations enrolled, the durations studied or the products analysed. Commentary accompanying these reviews has continued to recommend monitoring of mental health in people with existing psychiatric conditions, which remains a matter for prescribing clinicians rather than for labelling.
Why this belongs in a peptide reference library
Because it is a complete, dated, publicly documented example of a safety signal being opened, investigated across two regulatory systems and formally closed, which is rare. Most signals persist unresolved. It is also a demonstration of the gulf between what exists for licensed medicines and what exists for research material: three products here have a 107,910-participant randomised safety database and labelling that regulators actively revise. Compounds supplied for laboratory research have none of that, and no article on this site should ever be read as suggesting otherwise.
Frequently asked questions
Has the warning been removed already?
The FDA requested removal from application holders; implementing a labelling change is a process rather than an instant event, and other jurisdictions make their own decisions. The action to date is the request and the review supporting it.
Does this apply to all GLP-1 drugs?
The FDA communication names Saxenda, Wegovy and Zepbound. The EMA's earlier review covered dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide. Neither statement covers every compound in the class, and investigational agents have no labelling to change.
Why did this take two and a half years?
Because assembling participant-level data across 91 trials from multiple development programmes is a substantial undertaking, and because removing a warning requires more evidence than declining to add one. The delay reflects the evidentiary standard rather than inaction.
Does this change anything for someone taking one of these medicines?
It changes what the label says, not what any individual should do. Decisions about a prescription belong with the prescribing clinician. Nothing supplied on this site is a version of or an alternative to any of these medicines.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- FDAFDA Drug Safety Communication: FDA requests removal of suicidal behavior and ideation warning from GLP-1 receptor agonist medications, 13 January 2026fda.gov
- EMAEMA: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC), 8-11 April 2024ema.europa.eu
- PubMedBushi G et al., Association of GLP-1 Receptor Agonists With Risk of Suicidal Ideation and Behaviour: A Systematic Review and Meta-Analysis - Diabetes Metab Res Rev 2025 (PMID 39945396)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More Research & Regulatory News articles
- A Muscle Trial That Changed Its Primary EndpointVeru's QUALITY trial measured lean body mass. Its successor PLATEAU measures total body weight, which is a different question about the same combination.
- Four Arms, and Where the Participants WentREDEFINE 1 randomised 3,417 adults to CagriSema, semaglutide alone, cagrilintide alone or placebo. Its allocation ratio says what it was designed to answer.
- Less Weight Loss, and That Is the Expected ResultREDEFINE 2 reported a -13.7% weight change in adults with type 2 diabetes, against -20.4% in the trial without diabetes. That gap is a well-documented pattern.
- Superior to Semaglutide, by 0.16 Percentage PointsREIMAGINE 2 made semaglutide its primary comparator rather than placebo. The combination won, and the size of that win is the part actually worth reading.
- 7,101 Participants, and No Answer Until 2027REDEFINE 3 is the CagriSema cardiovascular outcomes trial. It enrolled 7,101 participants, and its primary completion date is not until September 2027.